N-[3-(氨基甲基)苯基]-N-甲基乙酰胺盐酸盐 | 849020-90-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[3-(氨基甲基)苯基]-N-甲基乙酰胺盐酸盐
• 中文别名: N-[3-(氨甲基)苯基]-N-甲基乙醛胺盐酸盐
• 英文名称: N-[3-(aminomethyl)phenyl]-N-methylacetamide hydrochloride
• 英文别名: N-[3-(aminomethyl)phenyl]-N-methylacetamide;hydrochloride
• CAS: 849020-90-2
• 化学式: C10H15ClN2O
• 分子量: 214.69
• InChiKey: ZAHFERYIAUVCQT-UHFFFAOYSA-N

物化性质

• 熔点：
  188-191°

计算性质

• 辛醇/水分配系数(LogP)：
  1.55
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

文献信息

• Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors
  申请人：Capraro Hans-Georg

  公开号：US20080261973A1

  公开（公告）日：2008-10-23

  The invention relates to sulphonamidoanilines of formula I, wherein A is N or CH, W, X, Y and Z are N or CH under the proviso that at least one of the three symbols W, X and Y represent CH, R 1 represents NR 4 R 5 or OR 4 , wherein R 4 represents optionally substituted alkyl, optionally substituted cycloalkyl optionally comprising one or two nitrogen or oxygen atoms, or substituted aryl, and R 5 represents hydrogen or unsubstituted or substituted alky, or R 4 and R 5 together with the nitrogen to which they are attached represent an optionally substituted five- or six-membered nitrogen containing monocyclic ring, an optionally substituted nitrogen containing fully saturated bicyclic ring, or an spirocyclic fully saturated ring system containing one or two nitrogen atoms, R 2 is hydrogen, lower alkenyl or alkyl, R 3 is alkyl which is unsubstituted or mono-, di- or trisubstituted by halogen; alkenyl or aryl, and their salts; processes for their preparation, their application in the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of diseases, a method for the treatment of such a disease and the use of such a compound—alone or in combination with one or more other pharmaceutically active compounds—for the manufacture of a pharmaceutical preparation for the treatment of a proliferative disease.

  本发明涉及式I的磺酰胺苯胺，其中A为N或CH，W、X、Y和Z为N或CH，但至少三个符号W、X和Y中的一个代表CH，R1代表NR4R5或OR4，其中R4代表可选取代的烷基，可选取代的环烷基，可包含一个或两个氮或氧原子的取代芳基；R5代表氢或未取代或取代的烷基，或R4和R5连同它们所连接的氮表示一个可选取代的五元或六元含氮单环环，一个可选取代的含氮完全饱和的双环环，或一个含有一或两个氮原子的螺环完全饱和环系统，R2为氢、低碳烯基或烷基，R3为未取代或单、二、三取代的卤素的烷基、烯基或芳基，以及它们的盐；它们的制备方法，它们在治疗人体或动物体中的应用，使用它们-独自或与一个或多个其他药理活性化合物结合-治疗疾病的方法，以及使用这种化合物-独自或与一个或多个其他药理活性化合物结合-制造治疗增殖性疾病的药物制剂。
• AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
  申请人：Harris Joel M.

  公开号：US20110105513A1

  公开（公告）日：2011-05-05

  Compounds of the Formula (I), where W represents CH or N; and Q represents —CN, —C(═NOH)NH 2 , —CONHR 1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof. Care adenosine A 2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.

  化合物的公式（I），其中W代表CH或N; Q代表—CN、—C(═NOH)NH2、—CONHR1或各种在此描述的杂环基团; 以及其药学上可接受的盐、溶剂化物、酯和前药。这些化合物是腺苷A2A受体拮抗剂，因此在中枢神经系统疾病，特别是帕金森病的治疗中是有用的。
• SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS
  申请人：Novartis AG

  公开号：EP1966210A2

  公开（公告）日：2008-09-10
• AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2282999B1

  公开（公告）日：2014-05-21
• US8415353B2
  申请人：——

  公开号：US8415353B2

  公开（公告）日：2013-04-09